Professor James Catto
MB ChB PhD FRCS(Urol)
Clinical Medicine, School of Medicine and Population Health
Professor of Urology
+44 114 215 9002
Full contact details
Clinical Medicine, School of Medicine and Population Health
GU19, G Floor
The Medical School
Beech Hill Road
葫芦影业
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
James Catto is NIHR Research Professor, Professor of Urology at the University of 葫芦影业 and an Honorary Consultant Urological Surgeon at 葫芦影业 Teaching Hospitals NHS Trust. He holds posts as an Honorary Senior Clinical Research fellow at the University of Oxford and Honorary Clinical Professor, Division of Surgery & Interventional Science, University College London. He qualified from Leeds University in 1994 and trained in York and 葫芦影业, UK before a fellowship in Brisbane, Australia.
James obtained a PhD in 2004 and runs a research team investigating the biology and management of urological cancers. He was awarded the European Association of Urology Best Thesis prize and the Bard Medal from BAUS for his PhD studies. In 2007 he was EAU-AUA exchange fellow with visits to the Johns Hopkins Medical School, The University of Chicago, Loyola University and The University of California, San Francisco. In 2010, he was awarded the Crystal Matula by the EAU, the Astellas Education Foundation award in 2011 and the Golden Telescope by BAUS in 2014.
James has raised over 拢26 million in peer-reviewed funding, published more than 300 primary research manuscripts, and has more than 30,000 citations on Google and an H factor of 72 on Scopus. His research funding includes a NIHR Research Professorship, a GSK Clinician Scientist fellowship, an MRC Clinical Research Fellowship, and grants from NIHR/MRC, The Wellcome Trust, CRUK, European Union, Royal College of Surgeons, The Urological Foundation and Yorkshire Cancer Research.
James is Editor In Chief of European Urology (2019 Impact factor 18.728). Please see the for further details.
- Research interests
-
James leads on Urology research, encompassing NIHR Clinical Lecturers, NIHR ACFs, post-docs, technicians, research nurses and PhD students. The team research the translational application of molecular biology to urological malignancies, in particular Bladder and Prostate Cancer, and partake in clinical trials focused on improving the care of patients with these cancers. James's particular interest is in the epigenetic alterations seen within these tumours.
James is also lead for 葫芦影业鈥檚 Cancer Research program. This multimodal data-driven patient-focussed program aims to improve survival for many common cancers across Yorkshire and create world leading expertise within 葫芦影业.
Current projects
James is currently Chief Investigator for i). GUSTO - Genotype of Urothelial cancer: Stratified Treatment and Oncological outcomes: Phase 2 study (funded by the MRC/NIHR), ii). iROC - A multicentre randomised controlled trial to compare the efficacy of Robotically Assisted Radical Cystectomy and intracorporeal urinary diversion with Open Radical Cystectomy in patients with bladder cancer (Funded by TUF), iii). YorkSure - Early detection of bladder cancer in Yorkshire: Feasibility assessments for implementing a targeted study in populations with high disease specific mortality risk (Funded by Yorkshire Cancer Research), iv). FINESSE - Increasing compliance with Active surveillance: A randomised trial evaluating the role of Finasteride (Funded by Yorkshire Cancer Research), v). Improving the outcomes from Bladder Cancer through the application of genomic stratification and development of novel agents (NIHR Research Professorship) and vi). Life and Bladder Cancer: The Yorkshire Cancer Research Bladder Cancer Patient Reported Outcomes Survey. (Funded by Yorkshire Cancer Research).
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . JAMA.
- . The Lancet Oncology, 23(5), 650-658.
- . European Urology.
- . European Urology.
- . Clinical Cancer Research.
- . Journal of Clinical Oncology.
- . PLoS ONE, 15(10).
- . European Urology, 78(5), 719-730.
- . Journal for ImmunoTherapy of Cancer, 8(1), e000928-e000928.
- . European Urology, 78(1), 29-42.
- . The Lancet, 395(10232), 1268-1277.
- . BJU International.
- . European Urology Supplements, 18(1), e1134-e1134.
- . The Lancet Oncology, 20(3), 436-447.
- . European Urology.
- . European Urology, 74(3), 294-306.
- . European Urology, 74(4), 531-534.
- . European Urology, 73(3), 363-371.
- . Cell, 171(3), 540-556.e25.
- . European Urology, 71(6), 915-923.
- . New England Journal of Medicine, 375(15), 1415-1424.
- . New England Journal of Medicine, 375(15), 1425-1437.
- . European Urology, 70(3), 458-466.
- . BJU International.
- . JAMA Oncology, 1(9), 1282-1290.
All publications
Books
Journal articles
- . European Urology.
- . Annals of Oncology, 35, S1271-S1271.
- . The Lancet Digital Health, 6(7), e507-e519.
- . BJU International, 134(3), 484-500.
- . Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
- . European Urology.
- . Journal of Urology, 211(5S).
- . European Urology, 85, S929-S930.
- . European Urology, 85, S1505-S1505.
- . European Urology, 85, S1874-S1875.
- . Urologic Oncology: Seminars and Original Investigations, 42, S53-S53.
- . Journal of Clinical Pathology, 77(5), 291-296.
- . The Journal of Pathology: Clinical Research, 10(2).
- . Journal of Clinical Oncology, 42(4_suppl), 586-586.
- . Journal of Clinical Oncology, 42(4_suppl), 584-584.
- . Journal of Clinical Oncology, 42(4_suppl), TPS710-TPS710.
- . Urologic Oncology: Seminars and Original Investigations.
- . BMJ Oncology, 2(1), e000092-e000092.
- . European Urology Oncology.
- . Annals of Oncology.
- . Annals of Oncology, 34, S1341-S1342.
- . Annals of Oncology, 34, S1224-S1224.
- . BMJ Open, 13(9), e076612-e076612.
- . European Urology, 84(4), e98-e99.
- . JCO Global Oncology, 9(Supplement_1), 80-80.
- . JAMA Network Open, 6(6).
- . Disease Models & Mechanisms, dmm.050110.
- . European Urology, 84(2), 176-190.
- . European Urology, 84(4), 393-405.
- . European Urology Focus.
- . Journal of Urology, 209(Supplement 4).
- . Bladder Cancer, 9(1), 59-71.
- . NEJM Evidence, 2(4).
- . PharmacoEconomics, 41(6), 633-650.
- . BJU International.
- . Journal of Clinical Oncology, 41(6_suppl), TPS396-TPS396.
- . Journal of Clinical Oncology, 41(6_suppl), TPS582-TPS582.
- . Journal of Clinical Oncology, 41(6_suppl), 503-503.
- . PharmacoEconomics - Open.
- . European Urology, 83, S219-S220.
- . European Urology Open Science, 49, 92-99.
- . European Urology Focus, 9(4), 631-636.
- . Quality of Life Research, 32(8), 2127-2135.
- . European Urology, 83(1), 90-91.
- . BJUI Compass.
- . JAMA, 328(12), 1258-1258.
- . European Urology.
- . European Urology.
- . Annals of Oncology, 33, S1330-S1330.
- . BJU International, 130(3), 275-276.
- . European Urology.
- . The Journal of Sexual Medicine, 19(9), 1431-1441.
- . BJU International, 130(3), 301-302.
- . Value in Health, 25(7), S288-S288.
- . American Journal of Obstetrics and Gynecology, 227(5), 735.e1-735.e25.
- . Cancer Causes & Control, 33(8), 1071-1081.
- . Journal of Clinical Oncology, 40(16_suppl), TPS5103-TPS5103.
- . BJU International, 129(6), 691-694.
- . JAMA.
- . BJU International.
- . European Urology.
- . The Lancet Oncology, 23(5), 650-658.
- . JMIR Research Protocols, 11(4).
- . Journal of Clinical Oncology, 40(6_suppl), 461-461.
- . Journal of Clinical Oncology, 40(6_suppl), TPS284-TPS284.
- . Journal of Clinical Oncology, 40(6_suppl), TPS579-TPS579.
- . European Urology, 81, S1125-S1125.
- . European Urology, 81, S507-S507.
- . European Urology, 81, S142-S143.
- . European Urology.
- . European Urology Focus.
- . The Journal of Cardiovascular Surgery, 62(6).
- . Anaesthesia, 77(1), 28-39.
- . European Urology Oncology, 5(1), 70-83.
- . BJS Open, 5(6).
- . European Urology Open Science, 33, 1-10.
- . Lancet Oncol.
- . BJUI Compass, 2(5), 338-347.
- . Journal of Urology, 206(Supplement 3).
- . European Urology Focus.
- . European Urology.
- . Anaesthesia, 76(11), 1454-1464.
- . European Urology.
- . European Urology, 79, S1385-S1385.
- . European Urology, 79, S1151-S1151.
- . European Urology.
- . European Urology.
- . The Journal of Thoracic and Cardiovascular Surgery, 162(2), e355-e372.
- . British Journal of Surgery, 108(9), 1056-1063.
- . Anaesthesia, 76(6), 748-758.
- . European Urology.
- . Journal of Clinical Oncology, 39(6_suppl), TPS505-TPS505.
- . Journal of Clinical Oncology, 39(6_suppl), TPS266-TPS266.
- . Journal of Clinical Oncology, 39(6_suppl), 455-455.
- . European Urology.
- . Clinical Cancer Research.
- . Cancer Causes & Control, 32(3), 261-269.
- . Journal of Clinical Oncology.
- . European Urology.
- . Actas Urol贸gicas Espa帽olas (English Edition), 44(10), 644-652.
- . PLoS ONE, 15(10).
- . Cancers, 12(10).
- . European Urology Oncology, 3(6), 811-811.
- . British Journal of Cancer, 123(7), 1063-1070.
- . European Urology.
- . BMJ Open, 10(9).
- . Actas Urol贸gicas Espa帽olas.
- . Annals of Oncology, 31, S548-S549.
- . Health Technology Assessment, 24(37), 1-175.
- . JCO Global Oncology(6), 1248-1257.
- . European Urology.
- . European Urology Oncology.
- . European Urology, 78(5), 719-730.
- . European Urology, 78(3), e139-e143.
- . European Urology Open Science, 19, 1-2.
- . European Urology Open Science, 19, e1999-e1999.
- . European Urology Open Science, 19, e2281-e2282.
- . European Urology Open Science, 19, e2280-e2280.
- . European Urology Open Science, 19, e1369-e1369.
- . European Urology Open Science, 19, e824-e825.
- . European Urology, 78(2), 209-220.
- . European Urology Focus.
- . Journal for ImmunoTherapy of Cancer, 8(1), e000928-e000928.
- . Journal of Clinical Oncology, 38(15_suppl), TPS3170-TPS3170.
- . European Urology, 78(1), 29-42.
- . Current Opinion in Urology, 30(3), 400-406.
- . Minerva Urologica e Nefrologica, 72(3).
- . European Urology, 77(6), 663-666.
- . The Journal of Urology, 203, e1087-e1088.
- . European Urology, 78(1), e18-e20.
- . European Urology, 78(2), 134-135.
- . The Lancet, 395(10232), 1268-1277.
- . BJU International.
- . European Urology, 77(6), 669-670.
- . European Urology Oncology, 3(3), 306-315.
- . International Journal of Surgery Protocols, 21, 8-12.
- . Journal of Clinical Oncology, 38(6_suppl), 446-446.
- . Journal of Clinical Oncology, 38(6_suppl), TPS385-TPS385.
- . Journal of Clinical Oncology, 38(6_suppl), TPS603-TPS603.
- . European Urology, 77(4), e94-e95.
- . BJU International, 125(4), 506-514.
- . European Urology.
- . European Urology.
- . Bladder Cancer, 6(4), 537-548.
- . European Urology, 77(5), 583-598.
- . World Journal of Urology, 38(8), 1959-1968.
- . European Urology, 77(1), 101-109.
- . European Urology Focus, 6(3), 427-429.
- . European Urology, 77(1), 1-2.
- . European Urology.
- . European Urology, 76(6), 790-813.
- . European Urology.
- . European Urology Oncology.
- . BMJ Open, 9(8), e020500corr1-e020500corr1.
- . Clinical Nutrition ESPEN, 31, 142-142.
- . BMJ Open, 9(6), e030850-e030850.
- . Journal of Clinical Epidemiology, 113, 200-213.
- . European Urology, 76(3), 368-380.
- . Journal of Clinical Oncology, 37(15_suppl), TPS4592-TPS4592.
- . European Urology Oncology, 2(3), 276-276.
- . European Urology, 76(2), 142-150.
- . European Urology, 76(2), 228-237.
- . Journal of Urology, 201(Supplement 4).
- . European Urology, 76(1), 57-58.
- . Journal of Urology, 201(Supplement 4).
- . European Urology Supplements, 18(1), e1134-e1134.
- . European Urology Supplements, 18(1), e762-e763.
- . European Urology Supplements, 18(1), e2147-e2148.
- . European Urology Supplements, 18(1), e1844-e1844.
- . Minerva Urologica e Nefrologica, 71(2).
- . European Radiology, 29(10), 5498-5506.
- . International Journal of Molecular Sciences, 20(6).
- . The Lancet Oncology, 20(3), 436-447.
- . The Lancet, 393(10172), 644-645.
- . Journal of Cancer Research and Clinical Oncology, 145(4), 811-820.
- . European Urology, 76(6), 872-873.
- . Immunity, 51(2), 411-412.
- . European Urology Oncology.
- . European Urology Focus.
- . European Urology, 75(1), 1-2.
- . European Urology, 75(2), e29-e30.
- . European Urology Oncology, 2(3), 265-273.
- . BJU International, 123(3), 380-382.
- . BJU International, 123(2), 284-292.
- . European Urology Focus, 5(4), 650-657.
- . Cell Reports, 23(1), 255-269.e4.
- . Progr猫s en Urologie, 28(13), 718-718.
- . Cell Reports, 25(5), 1304-1317.e5.
- . Cell Systems, 7(4), 422-437.e7.
- . European Urology.
- . European Urology Oncology, 1(4), 292-304.
- . European Urology, 74(3), 294-306.
- . Cancer Cell, 34(2), 211-224.e6.
- . BMJ Open, 8(8), e020500-e020500.
- . European Urology, 74(5), e109-e109.
- . Carcinogenesis, 39(8), 1094-1094.
- . Journal of Clinical Epidemiology, 99, 75-83.
- . European Urology, 74(3), 357-368.
- . Cell Reports, 23(12), 3698-3698.
- . BJU International, 122(6), 970-977.
- . European Urology, 74(3), e66-e66.
- . European Urology, 73(6), 925-933.
- . Carcinogenesis, 39(6), 798-807.
- . European Urology, 74(4), 531-534.
- . Journal of Clinical Oncology, 36(15_suppl), 3018-3018.
- . BMJ Open, 8(5), e022899-e022899.
- . British Journal of Cancer.
- . BJU International.
- . Cancer Cell, 33(4), 676-689.e3.
- . Cancer Cell, 33(4), 690-705.e9.
- . Cancer Cell, 33(4), 721-735.e8.
- . Cancer Cell, 33(4), 706-720.e9.
- . Cell, 173(2), 355-370.e14.
- . Cell, 173(2), 305-320.e10.
- . Cell, 173(2), 371-385.e18.
- . Cell, 173(2), 291-304.e6.
- . Cell, 173(2), 400-416.e11.
- . Cell, 173(2), 386-399.e12.
- . Cell, 173(2), 321-337.e10.
- . Cell, 173(2), 338-354.e15.
- . Cell Reports, 23(1), 282-296.e4.
- . Cell Reports, 23(1), 270-281.e3.
- . Cell Reports, 23(1), 239-254.e6.
- . Cell Reports, 23(1), 181-193.e7.
- . Cell Reports, 23(1), 227-238.e3.
- . Cell Reports, 23(1), 297-312.e12.
- . Cell Reports, 23(1), 313-326.e5.
- . Trials, 19(1).
- . Journal of Urology, 199(4S).
- . Journal of Urology, 199(4S).
- . Journal of Urology, 199(4S).
- . Journal of Urology, 199(4S).
- . Journal of Urology, 199(4S).
- . Journal of Clinical Epidemiology, 96, 35-46.
- . Cell Systems, 6(3), 271-281.e7.
- . BJU International.
- . JAMA, 319(9), 883-883.
- . European Urology Supplements, 17(2), e1024-e1025.
- . European Urology Supplements, 17(2), e1068-e1068.
- . European Urology Supplements, 17(2), e532-e533.
- . European Urology Supplements, 17(2), e1062-e1063.
- . European Urology Supplements, 17(2), e1431-e1432.
- . European Urology, 73(3), e51-e51.
- . European Urology, 73(3), 363-371.
- . European Urology, 74(1), 1-3.
- . Trials, 19(1).
- . European Urology, 74(5), 644-650.
- . Cell, 174(4), 1034-1035.
- . European Urology, 74(5), 597-608.
- . Cell Reports, 23(1), 194-212.e6.
- . Cell Reports, 23(1), 213-226.e3.
- . Cell Reports, 23(1), 172-180.e3.
- . Immunity, 48(4), 812-830.e14.
- . Cell Systems, 6(3), 282-300.e2.
- . European Urology, 73(3), 479-480.
- . European Urology, 73(5), 738-748.
- . Cell, 171(3), 540-556.e25.
- . IEEE Transactions on Fuzzy Systems, 26(3), 155-1577.
- . BMJ Open, 7(8).
- . BJU International, 120(2), 162-163.
- . European Urology, 72(2), 161-163.
- . European Urology, 71(6), 915-923.
- . BJU International.
- . PLOS ONE, 12(4).
- . European Urology Supplements, 16(3), e1316-e1318.
- . European Urology Supplements, 16(3), e1023-e1023.
- . European Urology Supplements, 16(3), e1440-e1442.
- . European Urology.
- . World Journal of Urology, 35(3), 355-365.
- . European Journal of Surgical Oncology (EJSO).
- . Journal of Cancer Survivorship.
- . European Radiology.
- . Minerva Urologica e Nefrologica, 69(1), 14-25.
- . European Urology.
- . Urology Practice, 4(4), 349-354.
- . European Urology Focus, 2(6), 565-566.
- . International Journal of Radiation Oncology*Biology*Physics, 96(5), 1127-1128.
- . BMJ Open, 6(12).
- . European Urology Focus, 2(5), 467-468.
- . Urologic Oncology: Seminars and Original Investigations, 34(11), 481-481.
- . Oncotarget.
- . New England Journal of Medicine, 375(15), 1415-1424.
- . New England Journal of Medicine, 375(15), 1425-1437.
- Consensus Guidelines for Reporting Prostate Cancer Gleason Grade Reply. JOURNAL OF UROLOGY, 196(4), 1322-1323.
- . European Urology Focus, 2(4), 339-340.
- . European Urology, 70(4), 547-548.
- . European Urology, 70(4), e106-e107.
- . European Urology Supplements, 15(7), 225-225.
- Consensus guidelines for reporting prostate cancer Gleason Grade Reply. BJU INTERNATIONAL, 118(3), E2-E2.
- . Clinical Oncology, 28(9), e92-e100.
- . European Urology, 70(3), 458-466.
- . BJU International.
- . BJU International, 118(3), E1-E2.
- . BJU International.
- . European Urology.
- . European Urology Focus.
- . Urology.
- . European Urology Focus, 2(3), 229-230.
- CONSENSUS GUIDELINES FOR REPORTING PROSTATE CANCER GLEASON GRADE. JOURNAL OF UROLOGY, 195(6), 1723-1723.
- . European Urology Focus, 2(2), 111-112.
- . European Urology Focus, 2(2), 113-121.
- . European Urology, 70(4), 649-660.
- . BJU International, 117(6), 849-849.
- . Urologic Oncology: Seminars and Original Investigations, 34(6), 253-253.
- . European Urology.
- . British Journal of Cancer, 114(8), 945-952.
- . European Urology Focus, 2(1), 1-2.
- . European Urology Focus, 2(1), 19-29.
- . European Urology, 69(4), 693-703.
- . Urology, 93, 1-1.
- . European Urology, 70(1), 1-1.
- . The Journal of Urology, 195(6), 1723-1723.
- . European Urology, 70(1), 176-187.
- . International Journal of Radiation Oncology*Biology*Physics, 95(4), 1092-1092.
- . European Urology, 69(2), 193-196.
- . European Urology Focus, 1(3), 215-216.
- . European Urology, 69(2), 183-185.
- . European Urology, 69(2), 186-190.
- . The American Journal of Surgical Pathology, 1-1.
- . JAMA Oncology, 1(9), 1224-1224.
- . Annals of Oncology, 26(12), 2392-2398.
- . JAMA Oncology, 1(9), 1282-1290.
- . BMJ Open, 5(9).
- . European Urology Focus, 1(2), 97-98.
- . British Journal of Cancer, 113(4), 634-644.
- . European Urology, 68(2), 238-253.
- . Cancer Epidemiology Biomarkers & Prevention, 24(7), 1121-1129.
- . Oncogene, 34(22), 2887-2896.
- . BJU International, 115(5), 753-763.
- . Contemporary Clinical Trials, 42, 26-40.
- . European Urology, 68(6), 1033-1044.
- . European Urology Supplements, 14(2), e747-e747.
- . European Urology Supplements, 14(2), e232-e232.
- . European Urology Supplements, 14(2), e527-e527a.
- . European Urology Supplements, 14(2), e227-e227b.
- . European Urology Supplements, 14(2), e426-e426b.
- . European Urology, 68(1), 1-2.
- . European Urology, 67(3), 363-375.
- . European Urology, 67(3), 423-431.
- . European Urology, 67(3), 460-467.
- . Nucleic Acids Research, 43(4), 2353-2366.
- . International Journal of Machine Learning and Computing, 5(1), 62-67.
- . European Urology, 67(3), 402-422.
- . European Urology, 67(3), 376-401.
- . Geophysical Research Letters, 42(20), 8596-8604.
- . Journal of Climate, 28(21), 8411-8429.
- . Human Molecular Genetics, 24(19), 5589-5602.
- . European Urology Focus, 1(1), 1-2.
- . European Urology Focus, 1(1), 82-89.
- . European Urology, 67(5), 876-888.
- . Cancer Epidemiology Biomarkers & Prevention, 24(1), 268-275.
- . European Urology, 67(2), 188-190.
- . European Urology.
- . Geophysical Research Letters, 41(21), 7642-7650.
- . Cancer Medicine, 3(5), 1225-1234.
- . Urologic Oncology: Seminars and Original Investigations, 32(7), 1078-1087.
- . European Urology, 66(3), 604-604.
- . Current Opinion in Urology, 24(5), 506-511.
- . Clinical Cancer Research, 20(20), 5311-5321.
- . Oncotarget, 5(15), 6375-6386.
- . Journal of Geophysical Research: Atmospheres, 119(11), 6609-6628.
- . Nat Commun, 5, 3756.
- . European Urology Supplements, 13(1), e995-e995.
- . European Urology Supplements, 13(1), e326-e326.
- . European Urology Supplements, 13(1), e43-e43.
- . Indian Journal of Urology, 30(2), 214-214.
- . Clinical Cancer Research, 20(7), 1990-2000.
- . BJU Int, 113(5), 811-812.
- . Environmental Research Letters, 9(3), 039501-039501.
- . Monthly Weather Review, 142(1), 343-363.
- . European Urology, 66(1), 118-119.
- . The Lancet Oncology, 15(10), 1109-1118.
- . Nature Communications, 5(1).
- . European Urology, 66(6), 982-986.
- . European Urology, 66(4), 628-632.
- . Nat Commun, 5, 4264.
- . European Urology, 66(3), 489-499.
- . Eur Urol, 65(2), 263-266.
- . Eur Urol, 66(2), 211-213.
- . The Library, 14(4), 465-466.
- . BJU International, n/a-n/a.
- . Cell Cycle Regulators.
- . Journal of Geophysical Research: Atmospheres, 118(19), 10,791-10,801.
- . International Journal of Surgery, 11(8), 727-727.
- . European Urology Supplements, 12(4), e1213, C105-e1213, C105.
- . Revista Brasileira de Parasitologia Veterin谩ria, 22(4), 502-510.
- . International Journal of Surgery, 11(8), 724-724.
- . Surgery (United Kingdom), 31(10), 523-529.
- . Surgery (United Kingdom), 31(10), 516-522.
- . European Urology, 64(3), 347-354.
- . British Journal of Cancer, 109(1), 50-59.
- . Eur Urol, 64(4), 567-576.
- . Br J Cancer, 108(7), 1534-1540.
- . European Urology Supplements, 12(1), e81-e82.
- . European Urology Supplements, 12(1), e568-e569.
- . European Urology Supplements, 12(1), e56-e56.
- . European Urology, 63(2), 379-385.
- . Nature Reviews Urology.
- . Eur Urol, 63(6), 1049-1058.
- . Journal of Clinical Urology, 6(5), 272-279.
- . European Urology.
- . European Urology.
- . European Urology, 64(6), 876-892.
- . European Urology.
- . Central European Journal of Urology, 66(1), 14-20.
- . Eur Urol, 63(5), 855-857.
- . J Urol, 189(3), 828-833.
- . World J Urol, 31(1), 21-29.
- . Eur Urol, 63(1), 145-154.
- . Eur Urol, 63(2), 234-241.
- . Eur Urol, 62(6), 1088-1096.
- Contemporary Occupational Bladder Cancer: A Systematic Review and Meta-Analysis of Recently Reported Exposures that Increase Risk. UROLOGY, 80(3), S1-S2.
- . Journal of Climate, 25(18), 6375-6382.
- . N Engl J Med, 367(4), 380.
- . New England Journal of Medicine, 367(4), 379-381.
- . Journal of Climate, 25(14), 5011-5029.
- . Archives of Surgery, 147(7).
- . Br J Cancer, 107(1), 123-128.
- . Cancer, 118(22), 5525-5534.
- . Molecular and Cellular Biology.
- . Eur Urol, 62(1), 76-77.
- . PLoS ONE, 7(3).
- . J Urol, 187(4), 1155-1156.
- . International Journal of Surgery, 10(8), S96-S96.
- . European Urology Supplements, 11(1), e435-e435a.
- . European Urology Supplements, 11(1), e1043-e1043a.
- . European Urology Supplements, 11(1), e166-e166.
- . European Urology Supplements, 11(1), e965-e965a.
- Differences in DNA methylation pattern of primary bladder tumours correlate with their metastatic potential. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E166-E166.
- Circulating microRNAs are associated with the development and progression of prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E435-U952.
- The long term outcome of high risk non-muscle invasive bladder cancer. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E965-EU26.
- Routine cystoscopic surveillance is ineffective in preventing death due to bladder cancer in patients with low risk disease. EUROPEAN UROLOGY SUPPLEMENTS, 11(1), E1043-EU179.
- . Expert Rev Anticancer Ther, 12(2), 271-281.
- . Br J Cancer, 106(4), 768-774.
- . BMJ, 344, d7894.
- . Cancer Research, 72(2 Supplement), A10-A10.
- . Environmental Research Letters, 7(2), 024014-024014.
- . Journal of Geophysical Research: Atmospheres, 117(D10), n/a-n/a.
- . Geophysical Research Letters, 39(10), n/a-n/a.
- . Occupational and Environmental Medicine, 69(4), 300-301.
- . Cancer Epidemiology, 36(1), e7-e12.
- Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study. BMJ, 344(7840).
- . Occup Environ Med, 69(4), 300-301.
- . Journal of Climate, 24(20), 5336-5352.
- . Eur Urol, 60(4), 867.
- . Br J Cancer, 105(7), 931-937.
- . The American Journal of Pathology, 179(2), 540-546.
- . Eur Urol, 60(5), 917-919.
- . Eur Urol, 60(4), 753-766.
- . World Journal of Urology, 29(3), 291-301.
- . Eur Urol, 60(1), 37-38.
- . Eur Urol, 60(1), 16-18.
- . European Urology Supplements, 10(2), 167-167.
- URINARY MICRORNA IN BLADDER CANCER - A POTENTIAL DIAGNOSTIC TOOL. EUR UROL SUPPL, 10(2), 81-81.
- . Eur Urol, 59(5), 719-720.
- Multiple markers in prostate cancer detection from ejaculate. BJU INTERNATIONAL, 107, 28-28.
- . Eur Urol, 59(5), 671-681.
- Educationand societyinthe middle ages and renaissance. Education and Society in the Middle Ages and Renaissance, 38, 1-952.
- A comparison of prostate cancer survival in England, Norway and Sweden: A population-based study. Cancer Epidemiology.
- . European Urology, 60(4), 753-766.
- Gastrointestinal Toxicity Following Radiotherapy for Prostate Cancer: A Ring of Fire. European Urology.
- . European Urology, 60(1), 16-18.
- . European Urology, 60(1), 37-38.
- . Epigenomics, 3(1), 35-45.
- . PLoS One, 6(1), e15810.
- . Methods Mol Biol, 676, 165-184.
- . Clin Cancer Res, 17(6), 1287-1296.
- . Pesquisa Veterinaria Brasileira, 30(11), 945-952.
- . J Urol, 184(2), 459-463.
- . Surgery (Oxford), 28(7), 323-330.
- . Cancers, 2(2), 1125-1154.
- . Journal of Climate, 23(7), 1621-1635.
- . British Journal of Cancer, 102(9), 1335-1340.
- . Pesquisa Veterinaria Brasileira, 30(3), 229-236.
- . Eur Urol, 57(3), 398-406.
- . Future Oncol, 6(2), 193-196.
- . Surgery, 28(12), 589-593.
- . European Urology, 57(3), 408-409.
- . BJU International, 106(5), 593-594.
- The role of genomic instability in the molecular pathogenesis of transitional cell carcinoma..
- . Cancer Res, 69(21), 8472-8481.
- . Revista Brasileira de Parasitologia Veterin谩ria, 18(04), 37-43.
- . Expert Rev Anticancer Ther, 9(7), 867-870.
- The differential expression of microRNAs in bladder cancer is associated with altered gene expression. BJU INTERNATIONAL, 103, 19-19.
- . Eur Urol, 55(6), 1487-1488.
- . Clin Cancer Res, 15(9), 3150-3155.
- . Eur Urol, 55(3), 650-657.
- . Revista Brasileira de Zootecnia, 38(2), 354-360.
- . PROTEOM CLIN APPL, 3(2), 197-212.
- . Histopathology, 53(5), 561-566.
- . Ci锚ncia Rural, 38(7), 2083-2091.
- UIJ - MicroRNA profiling of bladder cancer. UroToday International Journal, 1(3 SUPPL.).
- . Int J Radiat Oncol Biol Phys, 71(5), 1601-1602.
- . Eur Urol, 54(1), 11-12.
- . BJU Int, 101(11), 1448-1453.
- . Eur Urol, 53(4), 777-784.
- . European Urology Supplements, 7(3), 252-252.
- . J Proteome Res, 7(3), 897-907.
- . Int J Cancer, 122(4), 952-956.
- . UroToday International Journal, 01(03).
- . Surgery, 26(4), 150-153.
- . European Urology, Supplements, 7(5), 422-425.
- . Surgery, 26(4), 154-160.
- . Transactions of the Royal Historical Society, 17, 83-99.
- . Prostate, 67(16), 1761-1769.
- . J Urol, 178(4 Pt 1), 1150-1156.
- . Experiments in Fluids, 43(1), 135-146.
- . Tropical Animal Health and Production, 39(4), 287-296.
- . J Urol, 177(5), 1715-1720.
- . BJU Int, 99(5), 1031-1035.
- . Clin Cancer Res, 13(7), 2046-2053.
- . Clin Cancer Res, 13(6), 1720-1725.
- . European Urology Supplements, 6(2), 118-118.
- . European Urology Supplements, 6(2), 144-144.
- . European Urology Supplements, 6(2), 147-147.
- . European Urology Supplements, 6(2), 117-117.
- . European Urology Supplements, 6(2), 113-113.
- . Prostate, 67(4), 341-347.
- . European Urology, 51(2), 409-415.
- Artificial Intelligence techniques for the prediction of bladder cancer progression. ESANN 2005 Proceedings - 13th European Symposium on Artificial Neural Networks, 109-114.
- Artificial intelligence and bladder cancer arrays.. Verh Dtsch Ges Pathol, 91, 308-319.
- Improving gene array analysis: The application of artificial intelligence identifies novel biomarkers of non invasive papillary bladder cancer progression. PATHOLOGY RESEARCH AND PRACTICE, 203(5), 278-279.
- . European Urology, 50(5), 1102-1110.
- Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations - Editorial comment. EUROPEAN UROLOGY, 50(5), 1109-1110.
- . J Mol Med (Berl), 84(11), 883-885.
- . European Urology, 50(4), 862-862.
- . J Pathol, 209(3), 336-343.
- . J Urol, 175(6), 2323-2330.
- . Oncogene, 25(20), 2953-2960.
- . European Urology Supplements, 5(2), 37-37.
- . European Urology Supplements, 5(2), 114-114.
- . Oncogene, 25(13), 1984-1988.
- . BJU International, 97, 7-7.
- . BJU International, 97, 6-7.
- . BJU International, 97, 6-6.
- . J Urol, 175(2), 474-479.
- . IEEE Intelligent Systems, 646-651.
- . Foundation Years, 2(2), 80-82.
- Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract. Verhandlungen der Deutschen Gesellschaft f眉r Pathologie, 90, 244-252.
- . Oncol Rep, 15 Spec no., 1019-1022.
- . Prostate, 65(4), 322-330.
- . Postgrad Med J, 81(959), 599-603.
- . Pesquisa Veterinaria Brasileira, 25(3), 188-194.
- . Journal de Mycologie M茅dicale, 15(2), 63-68.
- Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder. BJU INTERNATIONAL, 95, 65-65.
- Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients. BJU INTERNATIONAL, 95, 63-64.
- . Urology, 65(6), 1233-1237.
- . J Clin Oncol, 23(13), 2903-2910.
- . J Urol, 173(4), 1237-1241.
- . European Urology Supplements, 4(3), 158-158.
- . European Urology Supplements, 4(3), 85-85.
- . European Urology Supplements, 4(3), 121-121.
- . European Urology Supplements, 4(3), 158-158.
- . Surgery (Oxford), 23(3), 114-116.
- . European Urology Supplements, 4(3), 18-18.
- . Surgery (Oxford), 23(3), 108-113.
- . Foundation Years, 1(3), 1-7.
- Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple urothelial carcinomas with mutator phenotype. Verhandlungen der Deutschen Gesellschaft f眉r Pathologie, 89, 225-233.
- . EAU Update Series, 3(3 SPEC. ISS.), 118-128.
- . EAU Update Series, 3(4), 180-188.
- . EAU Update Series, 3(4), 171-179.
- [Promoter methylation and microsatellite mutation reveals the clonal relationship of multiple urothelial carcinomas with mutator phenotype].. Verh Dtsch Ges Pathol, 89, 225-233.
- . Lancet, 364(9450), 2003-2004.
- . Urology, 64(6), 1238-1243.
- . Hum Pathol, 35(11), 1385-1391.
- . Br J Cancer, 91(4), 739-744.
- . Journal of Medical Genetics, 41(7), e91-e91.
- . Journal of Urology, 171(4S), 286-286.
- . European Urology Supplements, 3(2), 216-216.
- . European Urology Supplements, 3(2), 21-21.
- . European Urology Supplements, 3(2), 54-54.
- . European Urology Supplements, 3(2), 115-115.
- . Biomedical Engineering - Applications, Basis and Communications, 16(2), 49-58.
- . BJU Int, 93(1), 19-24.
- . Oncogene, 22(54), 8699-8706.
- Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.. Clin Cancer Res, 9(11), 4172-4177.
- . Int J Cancer, 105(4), 484-490.
- . European Urology Supplements, 2(1), 60-60.
- . European Urology Supplements, 2(1), 66-66.
- . Br J Cancer, 88(1), 31-35.
- . European Urology, Supplements, 2(6), 69.
- . European Urology, Supplements, 2(6), 70.
- . European Urology, Supplements, 2(6), 68.
- . Surgery (Oxford), 20(11), 255-257.
- . Surgery (Oxford), 20(11), 249-254.
- . Ann R Coll Surg Engl, 84(5), 309-313.
- . European Urology Supplements, 1(1), 22-22.
- . Pesquisa Veterinaria Brasileira, 21(4), 151-156.
- . Ann Clin Biochem, 38(Pt 6), 633-651.
- . Pesquisa Agropecuaria Brasileira, 36(9), 1205-1211.
- . Pesquisa Agropecuaria Brasileira, 35(10), 2099-2105.
- . Journal of Parenteral and Enteral Nutrition, 24(4), 240-243.
- . J Hepatobiliary Pancreat Surg, 6(3), 324-326.
- . Mycopathologia, 141(3), 123-125.
- . Postgrad Med J, 74(874), 501-502.
- Recurrence of adult groin hernias five years after repair in a district general hospital. BRITISH JOURNAL OF SURGERY, 85, 17-17.
- Topical glyceryl trinitrate cream for anal fissure.. Br J Surg, 85(6), 874-875.
- Closed drainage versus open packing of infected pancreatic necrosis. American Surgeon, 61(7), 612-618.
- Helminth parasites of capybaras (Hydrochaeris hydrochaeris) on sub-region of Nhecol芒ndia, Pantanal, Mato Grosso do Sul. Revista brasileira de biologia, 54(1), 39-48.
- Stoma care. Prescribers' Journal, 33(3), 111-121.
- . Surgical Endoscopy, 3(2), 106-108.
- . Endoscopy, 13(03), 128-130.
- . Archives of Surgery, 115(3), 273-273.
- . Archives of Surgery, 115(4), 540-540.
- . Past and Present, 71(1), 3-21.
- . The American Journal of Digestive Diseases, 19(6), 575-579.
- . The English Historical Review, LXXXII(CCCXXV), 764-771.
- . The British Journal of Radiology, 37(443), 859-860.
- . BMJ, 2(5151), 544-545.
- . BMJ, 1(2297), 11-26.
- . BJUI Compass.
- . BJU International.
- . New England Journal of Medicine.
- . BJUI Compass.
- . Health Technology Assessment, 1-65.
- . Soci茅t茅 Internationale d鈥橴rologie Journal, 5(3), 244-246.
- . Journal of Clinical Oncology.
- . Nature Reviews Urology.
- . BJU International.
- . JU Open Plus, 1(11).
- . JU Open Plus, 1(10).
- . BJU International.
- . BMJ, e071082-e071082.
- . New England Journal of Medicine.
- . BJU International.
- . Scientific Reports, 13(1).
- . Journal of Clinical Pathology.
- . British Journal of Surgery.
- . BJU International.
- . Expert Opinion on Investigational Drugs.
- . BJU International.
- .
- . Journal of Clinical Urology, 205141582092051-205141582092051.
- . World Journal of Urology.
- . Health Technology Assessment, 22(52), 1-96.
- . Cochrane Database of Systematic Reviews.
- .
- . PLoS ONE, 9(1), e86659-e86659.
- . Australian Meteorological and Oceanographic Journal, 63(1), 191-203.
Chapters
- In Pang KH, Catto JWF, Myat A & Haldar S (Ed.), Challenging Cases in Urological Surgery (pp. C12-C12.P147). Oxford University PressOxford
- , Robotic Urologic Surgery (pp. 627-637). Springer International Publishing
- , Basic Urological Sciences (pp. 208-217). CRC Press
- , Basic Urological Sciences (pp. 189-207). CRC Press
- , Urologic Principles and Practice (pp. 281-286). Springer International Publishing
- , Practical Tips in Urology (pp. 323-329). Springer London
- , Oxford Textbook of Fundamentals of Surgery (pp. 373-377). Oxford University Press
- , Upper Tract Urothelial Carcinoma (pp. 1-30). Springer New York
- , Practical Urology: Essential Principles and Practice (pp. 351-359). Springer London
- , The Cambridge Companion to Medieval English Mysticism (pp. 113-132). Cambridge University Press
- Cambridge University Press
- , Epigenomics (pp. 323-337). Cambridge University Press
Conference proceedings papers
- REMOTE DIGITAL SURVEILLANCE AND MACHINE LEARNING MODELLING TO PREDICT SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER-A SECONDARY OUTCOME ANALYSIS OF THE IROC TRIAL. JOURNAL OF UROLOGY, Vol. 211(5) (pp E793-E794)
- Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
- MEASURING OBJECTIVE RECOVERY OF ACTIVITY LEVELS USING WEARABLE DEVICES FOLLOWING OPEN VS INTRACORPOREAL ROBOTIC CYSTECTOMY: SECONDARY OUTCOMES ANALYSIS OF THE IROC RANDOMIZED TRIAL. JOURNAL OF UROLOGY, Vol. 209 (pp E985-E985)
- Pathology Against the Clock: Verification of Gene Expression Subtyping for the GUSTO Clinical Trial. JOURNAL OF PATHOLOGY, Vol. 261(SUPPL1) (pp S49-S49)
- ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED PROGRESSION FROM BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) HEALTH STATES. VALUE IN HEALTH, Vol. 25(7) (pp S288-S288)
- RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL. JOURNAL OF UROLOGY, Vol. 207(5) (pp E695-E695)
- DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(16)
- FACTORS ASSOCIATED WITH HIGH-QUALITY SURGERY FOLLOWING RADICAL CYSTECTOMY: ANALYSIS OF THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS (BAUS) CYSTECTOMY AUDIT. JOURNAL OF UROLOGY, Vol. 206 (pp E1057-E1058)
- . The Journal of Urology, Vol. 203 (pp e937-e937)
- Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
- DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 16 (pp 204-204)
- DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
- A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA). ONCOLOGY RESEARCH AND TREATMENT, Vol. 43 (pp 82-82)
- Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
- A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guerin (BCG) therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
- THE ROLE OF WEARABLE DEVICES AND CPET IN PREDICTING MAJOR COMPLICATIONS AFTER RADICAL CYSTECTOMY. JOURNAL OF UROLOGY, Vol. 203 (pp E937-E937)
- REPORTING RADICAL CYSTECTOMY OUTCOMES FOLLOWING IMPLEMENTATION OF ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOLS: A SYSTEMATIC REVIEW AND INDIVIDUAL PATIENT DATA META-ANALYSIS. JOURNAL OF UROLOGY, Vol. 203 (pp E1087-E1088)
- Low Levels of Intra-Tumour Heterogeneity in Non-Muscle Invasive Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S12-S12)
- NEGATIVE PREDICTIVE VALUE OF MULTI-PARAMETRIC MRI IN DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS. JOURNAL OF UROLOGY, Vol. 201(4) (pp E341-E341)
- COMPARATIVE COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY, AND EXTERNAL BEAM RADIOTHERAPY: LESSONS FROM PROTECT. JOURNAL OF UROLOGY, Vol. 201(4) (pp E417-E418)
- . European Urology Focus, Vol. 5(2) (pp 301-305)
- Results of POUT - A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 44-45)
- Patient-reported outcomes in men with advanced and localised disease: Results from the UK-wide Life After Prostate Cancer Diagnosis study. BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 11-11)
- Results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk non-muscle invasive bladder cancer (NMIBC). BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 39-39)
- SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. ANNALS OF ONCOLOGY, Vol. 29
- . Annals of Oncology, Vol. 29 (pp viii139-viii139)
- . Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS4594-TPS4594)
- RESULTS OF CALIBER: A PHASE II RANDOMISED FEASIBILITY TRIAL OF CHEMOABLATION VERSUS SURGICAL MANAGEMENT IN LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). JOURNAL OF UROLOGY, Vol. 199(4) (pp E1231-E1231)
- . European Urology Focus
- DISCHARGE OF LOW RISK NON MUSCLE INVASIVE BLADDER CANCER AFTER ONE YEAR: RESULTS OF A BAUS/BAUN NATIONAL SURVEY OF THE ADOPTION OF THE NICE BLADDER CANCER GUIDELINES RECOMMENDATIONS IN THE UK. JOURNAL OF UROLOGY, Vol. 199(4) (pp E98-E99)
- RESULTS OF POUT - A PHASE III RANDOMISED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (UTUC). JOURNAL OF UROLOGY, Vol. 199(4) (pp E213-E214)
- . Journal of Clinical Oncology, Vol. 36(6_suppl) (pp 40-40)
- . Journal of Clinical Oncology, Vol. 36(6_suppl) (pp 407-407)
- Exercise medicine for metastatic castrate-resistant prostate cancer: a supervised, periodised, progressive and autoregulated program combining resistance and aerobic exercise - the INTERVAL-MCRPC prescription. BJU INTERNATIONAL, Vol. 120 (pp 14-14)
- Evaluation of a short RNA within PCA3 in the predictive role for future cancer using non-malignant prostate biopsies. INTERNATIONAL JOURNAL OF UROLOGY, Vol. 24 (pp 144-144)
- . Journal of Urology, Vol. 197(4S)
- . Journal of Urology, Vol. 197(4S)
- . European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S244-S244)
- Identification of N6-adenosine methylated RNAs by m6A-seq within prostate cancer. INTERNATIONAL JOURNAL OF UROLOGY, Vol. 23 (pp 131-131)
- . Journal of Clinical Oncology, Vol. 34(15_suppl) (pp e16138-e16138)
- . Journal of Clinical Oncology, Vol. 34(15_suppl) (pp TPS5092-TPS5092)
- Workplace patterns and urothelial bladder cancer phenotype - can occupation increase the risk of developing advanced disease?. BJU INTERNATIONAL, Vol. 115 (pp 11-11)
- Workplace patterns and urothelial bladder cancer phenotype - can occupation increase the risk of developing advanced disease?. BJU INTERNATIONAL, Vol. 115 (pp 8-8)
- . Journal of Urology, Vol. 193(4S)
- . Journal of Urology, Vol. 193(4S)
- . Molecular and Cellular Biology
- . European Journal of Cancer, Vol. 50 (pp S98-S98)
- . Journal of Urology, Vol. 191(4S)
- . Journal of Urology, Vol. 189(4S)
- . Journal of Urology, Vol. 189(4S)
- Radial basis function neural-fuzzy model for microarray signature identification. BIOINFORMATICS 2013 - Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms (pp 134-139)
- . European Journal of Cancer, Vol. 48 (pp S87-S87)
- Snapshot of transurethral resection in the UK audit (STUKA). BJU INTERNATIONAL, Vol. 109 (pp 34-34)
- Hypoxia regulated miRNAs in bladder cancer. BJU INTERNATIONAL, Vol. 109 (pp 25-25)
- . Journal of Urology, Vol. 187(4S)
- The utilisation of microrna in urine samples as a potential diagnostic and prognostic biomarker in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98(6) (pp E1-E2)
- Role of expression of microrna machinery in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98(6) (pp E2-E2)
- PREOPERATIVE HYPERGLYCEMIA AND DIABETES AS RISK FACTORS FOR ANASTOMOTIC LEAK FOLLOWING COLECTOMY: ANALYSIS FROM THE MICHIGAN SURGICAL QUALITY COLLABORATIVE (MSQC).. DISEASES OF THE COLON & RECTUM, Vol. 54(5) (pp E43-E44)
- . Journal of Urology, Vol. 185(4S)
- Urinary MicroRNAs as a diagnostic biomarker in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98 (pp 52-52)
- Optimisation of microRNA extraction from urine samples with a view for a diagnostic and prognostic test for bladder cancer. BJU INTERNATIONAL, Vol. 106(1) (pp 55-55)
- Differential expression of microRNA processing machinery in Urothelial Carcinoma. BJU INTERNATIONAL, Vol. 106(1) (pp 54-54)
- Molecular diagnosis of localized prostate cancer by quantitative methylation-specific PCR gene patterns in urine cells obtained by prostate massage. JOURNAL OF UROLOGY, Vol. 177(4) (pp 95-95)
- Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation. JOURNAL OF UROLOGY, Vol. 177(4) (pp 295-296)
- Compared performance of microsatellite and methylation urinalysis in predicting recurrence in transitional cell carcinoma and definition of a diagnostic panel of markers by bayesian network analysis. JOURNAL OF UROLOGY, Vol. 177(4) (pp 296-296)
- Artificial intelligence re-analysis of gene array data identifies novel markers of urothelial cancer progression. JOURNAL OF UROLOGY, Vol. 177(4) (pp 297-298)
- FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis. CANCER RESEARCH, Vol. 66(8)
- FGFR3 mutations in upper urinary tract tumors are independent from microsatellite instability and associated with favorable outcome and a lower rate of bladder cancer recurrence. CANCER RESEARCH, Vol. 66(8)
- A gene promoter hypermethylation panel to detect transitional cell carcinoma (TCC) of the bladder. CANCER RESEARCH, Vol. 66(8)
- Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target. JOURNAL OF UROLOGY, Vol. 175(4) (pp 197-197)
- Artificial intelligence technique for gene expression profiling of urinary bladder cancer. 2006 3RD INTERNATIONAL IEEE CONFERENCE INTELLIGENT SYSTEMS, VOLS 1 AND 2 (pp 634-639)
- beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6)
- Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations. JOURNAL OF UROLOGY, Vol. 171(4) (pp 286-286)
- . Aircraft Engineering, Technology, and Operations Congress
- . Medicom Conference Report EAU 2022, 1 July 2022 - 1 July 2022.
Posters
- PD42-02 RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL.
- Comparing the ability of wearable devices and CPET to predict major complications following radical cystectomy.
Preprints
- Teaching activities
-
James teaches undergraduate medical students weekly and organises various uro-oncology study days for post-graduate urologists and surgeons. James is an educational supervisor to three trainee urologist and PhD mentor to 8 students.
- Professional activities and memberships
-
James is a member of the NCRI-CSG for Bladder and Kidney cancer, the EAU Scientific Congress Office and specialises in Uro-Oncology. He was part of the NICE Bladder Cancer Guideline development panel.
James is on the Trial Steering Groups for numerous trials including i). Life after prostate cancer (Funded by Prostate cancer UK and Movember 鈥 see ). ii). VANCE01 - A randomized phase I study to determine the safety and immunogenicity of ChAd-MVA vaccination compared to MVA alone with and without low dose cyclophosphamide in low and intermediate risk localised prostate cancer (Funded by European Union 鈥 see ), iii). POUT - A phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (Funded by CRUK 鈥 see ), iv). BladderPath - Image directed Redesign of Bladder Cancer Treatment Pathways (Funded by NIHR-HTA 鈥 see ), and v). CALIBER - A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancer (Funded by CRUK 鈥 see ).